Physician profile
Joanne Abbas
NPI 1649678285
$1,241.84
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $880 · 2022: $221 · 2023: $83.67 · 2024: $57.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $180.66 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $178.65 | 2021-2022 | |
| Abbvie INC. | $84.58 | 2021-2023 | Vraylar |
| Lilly USA, LLC | $78.61 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.82 | 2021-2022 | |
| Astellas Pharma US INC | $58.62 | 2021-2023 | Myrbetriq |
| Boston Scientific Corporation | $57.38 | 2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $55.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $48.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $47.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.05 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.67 | 2021 | |
| Abbott Laboratories | $39.42 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $36.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.76 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $26.68 | 2021 | |
| Recordati_rare_diseases_inc. | $25.08 | 2022 | |
| Eusa Pharma (US) LLC | $25.08 | 2022 | |
| Mylan Specialty L.P. | $24.54 | 2021 | |
| Dexcom, INC. | $21.64 | 2021 | |
| Insulet Corporation | $18.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.81 | 2022 | |
| Merck Sharp & Dohme LLC | $11.70 | 2021 | |
| Eisai INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.